<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">27162653</PMID><DateCompleted><Year>2016</Year><Month>05</Month><Day>10</Day></DateCompleted><DateRevised><Year>2020</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2072-1439</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>5</Issue><PubDate><Year>2016</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of thoracic disease</Title><ISOAbbreviation>J Thorac Dis</ISOAbbreviation></Journal><ArticleTitle>Prevalence of neutralizing antibodies to common respiratory viruses in intravenous immunoglobulin and in healthy donors in southern China.</ArticleTitle><Pagination><StartPage>803</StartPage><EndPage>812</EndPage><MedlinePgn>803-12</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.21037/jtd.2016.03.29</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Acute respiratory infections (ARIs) are a leading cause of death among children under the age of 5. However, there are no effective drugs for most of these severe viral infections. Passive immunotherapy with convalescent plasma or hyperimmune intravenous immunoglobulin (H-IVIG) is a potential therapeutic option for serious viral infections. It is important to find a suitable source of convalescent plasma and of H-IVIG containing high titer neutralizing antibodies (NAbs).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Sera from 96 healthy adult donors in southern China and commercially available IVIG were analyzed for the titers of NAb to several most common respiratory viruses including respiratory syncytial virus (RSV), seasonal influenza A (InfA), enterovirus 71 (EV71), coxsackievirus A16 (CA16), adenovirus type 3 (Ad3) and a recent epidemic adenovirus type 55 (Ad55) by microneutralization test.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A high proportion of samples from healthy adult donors were positive for NAbs (&gt;16) to all the viruses except Ad55. A different proportion of these samples had high NAb titers (&gt;512) for InfA (25%), Ad3 (17.71%), RSV (9.38%), EV71 (1.04%), CA16 (3.13%), and Ad55 (4.17%). Commercially available IVIG had high NAb titers to InfA and Ad3 (&gt;1,000) and lower NAb titers to RSV [320], EV71 [160], and CA16 [160]. Strikingly, IVIG also had a high NAb titer to Ad55 (&gt;1,000).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Convalescent plasma could be screened from healthy blood volunteers to establish blood banks and to prepare specific H-IVIG for treating severe ARIs caused by common respiratory viruses.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Xingui</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>1 Department of Medical Genetics and Cell Biology, School of Basic Science, Guangzhou Medical University, Guangzhou 511436, China ; 2 State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 510120, China ; 3 Dongguan Institute of Pediatrics, Dongguan Children's Hospital, Dongguan 523325, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Zaixue</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>1 Department of Medical Genetics and Cell Biology, School of Basic Science, Guangzhou Medical University, Guangzhou 511436, China ; 2 State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 510120, China ; 3 Dongguan Institute of Pediatrics, Dongguan Children's Hospital, Dongguan 523325, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Qiang</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>1 Department of Medical Genetics and Cell Biology, School of Basic Science, Guangzhou Medical University, Guangzhou 511436, China ; 2 State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 510120, China ; 3 Dongguan Institute of Pediatrics, Dongguan Children's Hospital, Dongguan 523325, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>1 Department of Medical Genetics and Cell Biology, School of Basic Science, Guangzhou Medical University, Guangzhou 511436, China ; 2 State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 510120, China ; 3 Dongguan Institute of Pediatrics, Dongguan Children's Hospital, Dongguan 523325, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Xiaomei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>1 Department of Medical Genetics and Cell Biology, School of Basic Science, Guangzhou Medical University, Guangzhou 511436, China ; 2 State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 510120, China ; 3 Dongguan Institute of Pediatrics, Dongguan Children's Hospital, Dongguan 523325, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Wenkuan</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>1 Department of Medical Genetics and Cell Biology, School of Basic Science, Guangzhou Medical University, Guangzhou 511436, China ; 2 State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 510120, China ; 3 Dongguan Institute of Pediatrics, Dongguan Children's Hospital, Dongguan 523325, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Xiaohong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>1 Department of Medical Genetics and Cell Biology, School of Basic Science, Guangzhou Medical University, Guangzhou 511436, China ; 2 State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 510120, China ; 3 Dongguan Institute of Pediatrics, Dongguan Children's Hospital, Dongguan 523325, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Rong</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>1 Department of Medical Genetics and Cell Biology, School of Basic Science, Guangzhou Medical University, Guangzhou 511436, China ; 2 State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 510120, China ; 3 Dongguan Institute of Pediatrics, Dongguan Children's Hospital, Dongguan 523325, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Xiaobo</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>1 Department of Medical Genetics and Cell Biology, School of Basic Science, Guangzhou Medical University, Guangzhou 511436, China ; 2 State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 510120, China ; 3 Dongguan Institute of Pediatrics, Dongguan Children's Hospital, Dongguan 523325, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Qingming</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>1 Department of Medical Genetics and Cell Biology, School of Basic Science, Guangzhou Medical University, Guangzhou 511436, China ; 2 State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 510120, China ; 3 Dongguan Institute of Pediatrics, Dongguan Children's Hospital, Dongguan 523325, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>J Thorac Dis</MedlineTA><NlmUniqueID>101533916</NlmUniqueID><ISSNLinking>2072-1439</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute respiratory infection (ARI)</Keyword><Keyword MajorTopicYN="N">convalescent plasma</Keyword><Keyword MajorTopicYN="N">intravenous immunoglobulin (IVIG)</Keyword><Keyword MajorTopicYN="N">neutralizing antibodies (NAbs)</Keyword><Keyword MajorTopicYN="N">seroprevalence</Keyword></KeywordList><CoiStatement><i>Conflicts of Interest:</i> The authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>5</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27162653</ArticleId><ArticleId IdType="pmc">PMC4842828</ArticleId><ArticleId IdType="doi">10.21037/jtd.2016.03.29</ArticleId><ArticleId IdType="pii">jtd-08-05-803</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization (WHO). Acute respiratory infections. Available online: http://www.who.int/topics/respiratory_tract_diseases/en/</Citation></Reference><Reference><Citation>Ruuskanen O, Lahti E, Jennings LC, et al. Viral pneumonia. Lancet 2011;377:1264-75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7138033</ArticleId><ArticleId IdType="pubmed">21435708</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu WK, Liu Q, Chen de H, et al. Epidemiology of acute respiratory infections in children in Guangzhou: a three-year study. PLoS One 2014;9:e96674.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4010508</ArticleId><ArticleId IdType="pubmed">24797911</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams BG, Gouws E, Boschi-Pinto C, et al. Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infect Dis 2002;2:25-32.</Citation><ArticleIdList><ArticleId IdType="pubmed">11892493</ArticleId></ArticleIdList></Reference><Reference><Citation>Berkley JA, Munywoki P, Ngama M, et al. Viral etiology of severe pneumonia among Kenyan infants and children. JAMA 2010;303:2051-7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2968755</ArticleId><ArticleId IdType="pubmed">20501927</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcone DN, Ellis A, Videla C, et al. Viral etiology of acute respiratory infections in hospitalized and outpatient children in Buenos Aires, Argentina. Pediatr Infect Dis J 2013;32:e105-10.</Citation><ArticleIdList><ArticleId IdType="pubmed">23190781</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandkovsky U, Vargas L, Florescu DF. Adenovirus: current epidemiology and emerging approaches to prevention and treatment. Curr Infect Dis Rep 2014;16:416.</Citation><ArticleIdList><ArticleId IdType="pubmed">24908344</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng J, Qian Y, Zhao LQ, et al. Identification and typing of adenovirus from acute respiratory infections in pediatric patients in Beijing from 2003 to 2012. Bing Du Xue Bao 2013;29:615-20.</Citation><ArticleIdList><ArticleId IdType="pubmed">24520767</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu QB, Tong YG, Wo Y, et al. Epidemiology of human adenovirus and molecular characterization of human adenovirus 55 in China, 2009-2012. Influenza Other Respir Viruses 2014;8:302-8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4181478</ArticleId><ArticleId IdType="pubmed">24467816</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao B, Huang GH, Pu ZH, et al. Emergence of community-acquired adenovirus type 55 as a cause of community-onset pneumonia. Chest 2014;145:79-86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7094559</ArticleId><ArticleId IdType="pubmed">24551881</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelesidis T, Mastoris I, Metsini A, et al. How to approach and treat viral infections in ICU patients. BMC Infect Dis 2014;14:321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4289200</ArticleId><ArticleId IdType="pubmed">25431007</ArticleId></ArticleIdList></Reference><Reference><Citation>Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 2015;211:80-90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4264590</ArticleId><ArticleId IdType="pubmed">25030060</ArticleId></ArticleIdList></Reference><Reference><Citation>Luke TC, Casadevall A, Watowich SJ, et al. Hark back: passive immunotherapy for influenza and other serious infections. Crit Care Med 2010;38:e66-73.</Citation><ArticleIdList><ArticleId IdType="pubmed">20154602</ArticleId></ArticleIdList></Reference><Reference><Citation>Hui DS, Lee N, Chan PK. Adjunctive therapies and immunomodulatory agents in the management of severe influenza. Antiviral Res 2013;98:410-6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7132367</ArticleId><ArticleId IdType="pubmed">23578727</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med 2007;357:1450-1.</Citation><ArticleIdList><ArticleId IdType="pubmed">17914053</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung IF, To KK, Lee CK, et al. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest 2013;144:464-73.</Citation><ArticleIdList><ArticleId IdType="pubmed">23450336</ArticleId></ArticleIdList></Reference><Reference><Citation>Hohenadl C, Wodal W, Kerschbaum A, et al. Hyperimmune intravenous immunoglobulin containing high titers of pandemic H1N1 hemagglutinin and neuraminidase antibodies provides dose-dependent protection against lethal virus challenge in SCID mice. Virol J 2014;11:70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3996311</ArticleId><ArticleId IdType="pubmed">24739285</ArticleId></ArticleIdList></Reference><Reference><Citation>Park UJ, Hyun SK, Kim HT, et al. Successful treatment of disseminated adenovirus infection with ribavirin and intravenous immunoglobulin in an adult renal transplant recipient: a case report. Transplant Proc 2015;47:791-3.</Citation><ArticleIdList><ArticleId IdType="pubmed">25891733</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HK, Lee CK, Hung IF, et al. Practical limitations of convalescent plasma collection: a case scenario in pandemic preparation for influenza A (H1N1) infection. Transfusion 2010;50:1967-71.</Citation><ArticleIdList><ArticleId IdType="pubmed">20412524</ArticleId></ArticleIdList></Reference><Reference><Citation>Leider JP, Brunker PA, Ness PM. Convalescent transfusion for pandemic influenza: preparing blood banks for a new plasma product? Transfusion 2010;50:1384-98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7201862</ArticleId><ArticleId IdType="pubmed">20158681</ArticleId></ArticleIdList></Reference><Reference><Citation>Parry RP, Tettmar KI, Hoschler K, et al. Strategies for screening blood donors to source convalescent H1N1v plasma for intervention therapy. Vox Sang 2012;103:107-12.</Citation><ArticleIdList><ArticleId IdType="pubmed">22404076</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Xie YW, Hong J, et al. Purification of severe acute respiratory syndrome hyperimmune globulins for intravenous injection from convalescent plasma. Transfusion 2005;45:1160-4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7201861</ArticleId><ArticleId IdType="pubmed">15987362</ArticleId></ArticleIdList></Reference><Reference><Citation>Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. N Engl J Med 1988;319:902-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">2901668</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapel HM, Lee M, Hargreaves R, et al. Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. Lancet 1994;343:1059-63.</Citation><ArticleIdList><ArticleId IdType="pubmed">7909099</ArticleId></ArticleIdList></Reference><Reference><Citation>Magny JF, Bremard-Oury C, Brault D, et al. Intravenous immunoglobulin therapy for prevention of infection in high-risk premature infants: report of a multicenter, double-blind study. Pediatrics 1991;88:437-43.</Citation><ArticleIdList><ArticleId IdType="pubmed">1881720</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowden RA, Fisher LD, Rogers K, et al. Cytomegalovirus (CMV)-specific intravenous immunoglobulin for the prevention of primary CMV infection and disease after marrow transplant. J Infect Dis 1991;164:483-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">1651360</ArticleId></ArticleIdList></Reference><Reference><Citation>Crabol Y, Terrier B, Rozenberg F, et al. Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus b19 infection: a retrospective study of 10 patients and review of the literature. Clin Infect Dis 2013;56:968-77.</Citation><ArticleIdList><ArticleId IdType="pubmed">23243178</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong DK, Tremoulet AH, Burns JC, et al. Cross-reactive neutralizing antibody against pandemic 2009 H1N1 influenza a virus in intravenous immunoglobulin preparations. Pediatr Infect Dis J 2011;30:67-9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3044211</ArticleId><ArticleId IdType="pubmed">20724956</ArticleId></ArticleIdList></Reference><Reference><Citation>Kubota-Koketsu R, Yunoki M, Okuno Y, et al. Significant neutralizing activities against H2N2 influenza A viruses in human intravenous immunoglobulin lots manufactured from 1993 to 2010. Biologics 2012;6:245-7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3413397</ArticleId><ArticleId IdType="pubmed">22888217</ArticleId></ArticleIdList></Reference><Reference><Citation>Hancock K, Veguilla V, Lu X, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009;361:1945-52.</Citation><ArticleIdList><ArticleId IdType="pubmed">19745214</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry Dunand CJ, Leon PE, Kaur K, et al. Preexisting human antibodies neutralize recently emerged H7N9 influenza strains. J Clin Invest 2015;125:1255-68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4362269</ArticleId><ArticleId IdType="pubmed">25689254</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S, Huang W, Zhou X, et al. Seroprevalence of neutralizing antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus type-68 in healthy Chinese adults. J Med Virol 2013;85:1077-84.</Citation><ArticleIdList><ArticleId IdType="pubmed">23588735</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Liu Y, Zhang Y, et al. Pre-existing immunity with high neutralizing activity to 2009 pandemic H1N1 influenza virus in Shanghai population. PLoS One 2013;8:e58810.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3602581</ArticleId><ArticleId IdType="pubmed">23527030</ArticleId></ArticleIdList></Reference><Reference><Citation>Li GM, Chiu C, Wrammert J, et al. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc Natl Acad Sci U S A 2012;109:9047-52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3384143</ArticleId><ArticleId IdType="pubmed">22615367</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller MS, Gardner TJ, Krammer F, et al. Neutralizing antibodies against previously encountered influenza virus strains increase over time: a longitudinal analysis. Sci Transl Med 2013;5:198ra107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4091683</ArticleId><ArticleId IdType="pubmed">23946196</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu R, Ekiert DC, Krause JC, et al. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science 2010;328:357-60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2897825</ArticleId><ArticleId IdType="pubmed">20339031</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>